- Home
- SJT vs OLMA Comparison
SJT vs OLMA Comparison
Compare SJT & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- OLMA
- Stock Information
- Founded
- SJT 1980
- OLMA 2006
- Country
- SJT United States
- OLMA United States
- Employees
- SJT N/A
- OLMA N/A
- Industry
- SJT Oil & Gas Production
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- OLMA Health Care
- Exchange
- SJT Nasdaq
- OLMA Nasdaq
- Market Cap
- SJT 280.6M
- OLMA 299.7M
- IPO Year
- SJT N/A
- OLMA 2020
- Fundamental
- Price
- SJT $5.68
- OLMA $4.71
- Analyst Decision
- SJT
- OLMA Strong Buy
- Analyst Count
- SJT 0
- OLMA 4
- Target Price
- SJT N/A
- OLMA $24.50
- AVG Volume (30 Days)
- SJT 176.6K
- OLMA 572.4K
- Earning Date
- SJT 08-13-2025
- OLMA 08-05-2025
- Dividend Yield
- SJT N/A
- OLMA N/A
- EPS Growth
- SJT N/A
- OLMA N/A
- EPS
- SJT 0.02
- OLMA N/A
- Revenue
- SJT $1,931,777.00
- OLMA N/A
- Revenue This Year
- SJT N/A
- OLMA N/A
- Revenue Next Year
- SJT N/A
- OLMA N/A
- P/E Ratio
- SJT $256.74
- OLMA N/A
- Revenue Growth
- SJT N/A
- OLMA N/A
- 52 Week Low
- SJT $3.21
- OLMA $2.86
- 52 Week High
- SJT $7.22
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- SJT 38.74
- OLMA 53.79
- Support Level
- SJT $5.78
- OLMA $4.40
- Resistance Level
- SJT $6.42
- OLMA $4.76
- Average True Range (ATR)
- SJT 0.21
- OLMA 0.28
- MACD
- SJT -0.03
- OLMA 0.00
- Stochastic Oscillator
- SJT 0.41
- OLMA 53.12
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.